JP2016098233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016098233A5 JP2016098233A5 JP2016030270A JP2016030270A JP2016098233A5 JP 2016098233 A5 JP2016098233 A5 JP 2016098233A5 JP 2016030270 A JP2016030270 A JP 2016030270A JP 2016030270 A JP2016030270 A JP 2016030270A JP 2016098233 A5 JP2016098233 A5 JP 2016098233A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- antibody
- residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 43
- 206010028980 Neoplasm Diseases 0.000 claims 19
- 229940127276 delta-like ligand 3 Drugs 0.000 claims 18
- 125000005647 linker group Chemical group 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 7
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 5
- 239000011230 binding agent Substances 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 230000000306 recurrent effect Effects 0.000 claims 4
- 108010016626 Dipeptides Proteins 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 claims 2
- 102100038518 Calcitonin Human genes 0.000 claims 2
- 102000010792 Chromogranin A Human genes 0.000 claims 2
- 108010038447 Chromogranin A Proteins 0.000 claims 2
- 102100036466 Delta-like protein 3 Human genes 0.000 claims 2
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- 102000005650 Notch Receptors Human genes 0.000 claims 2
- 108010070047 Notch Receptors Proteins 0.000 claims 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 claims 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 102000005157 Somatostatin Human genes 0.000 claims 2
- 108010056088 Somatostatin Proteins 0.000 claims 2
- 102000004874 Synaptophysin Human genes 0.000 claims 2
- 108090001076 Synaptophysin Proteins 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 108010035075 Tyrosine decarboxylase Proteins 0.000 claims 2
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 claims 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000000955 neuroendocrine Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 2
- 229960000553 somatostatin Drugs 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 claims 1
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical group NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims 1
- RVLOMLVNNBWRSR-KNIFDHDWSA-N (2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O RVLOMLVNNBWRSR-KNIFDHDWSA-N 0.000 claims 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 102100022142 Achaete-scute homolog 1 Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 1
- 101000901099 Homo sapiens Achaete-scute homolog 1 Proteins 0.000 claims 1
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 claims 1
- 101000932890 Homo sapiens Calcitonin gene-related peptide 1 Proteins 0.000 claims 1
- 101001002170 Homo sapiens Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial Proteins 0.000 claims 1
- 101000994437 Homo sapiens Protein jagged-1 Proteins 0.000 claims 1
- 101001067250 Homo sapiens Transcription cofactor HES-6 Proteins 0.000 claims 1
- 101000843556 Homo sapiens Transcription factor HES-1 Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 claims 1
- OZILORBBPKKGRI-RYUDHWBXSA-N Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 OZILORBBPKKGRI-RYUDHWBXSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100032702 Protein jagged-1 Human genes 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 102100034424 Transcription cofactor HES-6 Human genes 0.000 claims 1
- 102100030798 Transcription factor HES-1 Human genes 0.000 claims 1
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 claims 1
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 claims 1
- 102100025038 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Human genes 0.000 claims 1
- 101710186825 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 claims 1
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 1
- 229930195731 calicheamicin Natural products 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- -1 maytansinoid Chemical compound 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 108010018625 phenylalanylarginine Proteins 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000005102 tumor initiating cell Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 108010073969 valyllysine Proteins 0.000 claims 1
- CWPJNVNEPSACMM-FZMZJTMJSA-N CC(C)[C@@H](C(N[C@@H](C)C(Nc1ccc(COC(N)=O)cc1)=O)=O)NC Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(Nc1ccc(COC(N)=O)cc1)=O)=O)NC CWPJNVNEPSACMM-FZMZJTMJSA-N 0.000 description 1
- 0 CCC(*)CN(CC(*)*c1c2c(*)c(*)c(**(*(c3c(*)c(N=C)c(C(N4[C@](C)C[C@@](C)C(C)C4)=O)c(*)c3*)=C)=C)c1*)C2=O Chemical compound CCC(*)CN(CC(*)*c1c2c(*)c(*)c(**(*(c3c(*)c(N=C)c(C(N4[C@](C)C[C@@](C)C(C)C4)=O)c(*)c3*)=C)=C)c1*)C2=O 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603173P | 2012-02-24 | 2012-02-24 | |
| US61/603,173 | 2012-02-24 | ||
| US201261719803P | 2012-10-29 | 2012-10-29 | |
| US61/719,803 | 2012-10-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558882A Division JP6089047B2 (ja) | 2012-02-24 | 2013-02-22 | Ｄｌｌ３モジュレーター及び使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018102094A Division JP2018162257A (ja) | 2012-02-24 | 2018-05-29 | Ｄｌｌ３モジュレーター及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016098233A JP2016098233A (ja) | 2016-05-30 |
| JP2016098233A5 true JP2016098233A5 (enExample) | 2017-01-12 |
Family
ID=47790544
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558882A Expired - Fee Related JP6089047B2 (ja) | 2012-02-24 | 2013-02-22 | Ｄｌｌ３モジュレーター及び使用方法 |
| JP2016030269A Expired - Fee Related JP6010241B2 (ja) | 2012-02-24 | 2016-02-19 | Ｄｌｌ３モジュレーター及び使用方法 |
| JP2016030270A Pending JP2016098233A (ja) | 2012-02-24 | 2016-02-19 | Ｄｌｌ３モジュレーター及び使用方法 |
| JP2018102094A Pending JP2018162257A (ja) | 2012-02-24 | 2018-05-29 | Ｄｌｌ３モジュレーター及び使用方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558882A Expired - Fee Related JP6089047B2 (ja) | 2012-02-24 | 2013-02-22 | Ｄｌｌ３モジュレーター及び使用方法 |
| JP2016030269A Expired - Fee Related JP6010241B2 (ja) | 2012-02-24 | 2016-02-19 | Ｄｌｌ３モジュレーター及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018102094A Pending JP2018162257A (ja) | 2012-02-24 | 2018-05-29 | Ｄｌｌ３モジュレーター及び使用方法 |
Country Status (31)
| Country | Link |
|---|---|
| US (31) | US9089616B2 (enExample) |
| EP (4) | EP3093293A1 (enExample) |
| JP (4) | JP6089047B2 (enExample) |
| KR (1) | KR20150003169A (enExample) |
| CN (1) | CN104520324A (enExample) |
| AU (3) | AU2013203459B2 (enExample) |
| BR (1) | BR112014020826A8 (enExample) |
| CA (2) | CA2865404C (enExample) |
| CL (2) | CL2014002240A1 (enExample) |
| CO (1) | CO7111274A2 (enExample) |
| CY (1) | CY1119590T1 (enExample) |
| DK (1) | DK2817338T3 (enExample) |
| ES (2) | ES2645272T3 (enExample) |
| HK (3) | HK1231486A1 (enExample) |
| HR (1) | HRP20171549T1 (enExample) |
| HU (1) | HUE037021T2 (enExample) |
| IL (2) | IL234155B (enExample) |
| LT (1) | LT2817338T (enExample) |
| ME (1) | ME02928B (enExample) |
| MX (2) | MX2014010074A (enExample) |
| NZ (1) | NZ628804A (enExample) |
| PE (2) | PE20190658A1 (enExample) |
| PH (1) | PH12014501876A1 (enExample) |
| PL (1) | PL2817338T3 (enExample) |
| PT (1) | PT2817338T (enExample) |
| RS (1) | RS56443B1 (enExample) |
| RU (1) | RU2014138474A (enExample) |
| SG (2) | SG11201405131XA (enExample) |
| SI (1) | SI2817338T1 (enExample) |
| SM (1) | SMT201700467T1 (enExample) |
| WO (1) | WO2013126746A2 (enExample) |
Families Citing this family (142)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2530091T1 (en) * | 2010-01-29 | 2018-06-29 | Chugai Seiyaku Kabushiki Kaisha | PROTITELO ANTI-DLL3 |
| PL2817338T3 (pl) | 2012-02-24 | 2017-12-29 | Abbvie Stemcentrx Llc | Modulatory DLL3 i sposoby zastosowania |
| WO2014031174A1 (en) | 2012-08-24 | 2014-02-27 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| PL2958944T3 (pl) * | 2013-02-22 | 2019-09-30 | Abbvie Stemcentrx Llc | Koniugaty przeciwciało anty-DLL3-PBD i ich zastosowania |
| KR20160044042A (ko) | 2013-08-28 | 2016-04-22 | 스템센트알엑스 인코포레이티드 | 부위-특이적 항체 접합 방법 및 조성물 |
| MX2016002545A (es) * | 2013-08-28 | 2016-06-17 | Stemcentrx Inc | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y metodos de uso. |
| BR112015032713B1 (pt) | 2013-09-17 | 2023-03-21 | Obi Pharma, Inc | Composto, composição farmacêutica, uso de uma quantidade terapeuticamente efetiva da composição farmacêutica, e uso do composto |
| TWI712421B (zh) | 2013-11-11 | 2020-12-11 | 日商中外製藥股份有限公司 | 含改變的抗體可變區之抗原結合分子 |
| TWI700295B (zh) * | 2013-12-16 | 2020-08-01 | 馬來西亞商Ｍａｂ探索私人有限公司 | 對會感染人類之腸病毒具有專一性之抗體 |
| CA2939941A1 (en) * | 2014-02-21 | 2015-08-27 | Abbvie Stemcentrx Llc | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| EP3662928A1 (en) | 2014-04-10 | 2020-06-10 | OBI Pharma Inc. | Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof |
| IL240241B (en) * | 2014-07-31 | 2019-11-28 | Israel Institute For Biological Res | Antibodies directed to bacillus anthracis protective antigen |
| EP3174901B1 (en) | 2014-07-31 | 2019-06-26 | Amgen Research (Munich) GmbH | Optimized cross-species specific bispecific single chain antibody constructs |
| TWI880146B (zh) | 2014-11-11 | 2025-04-11 | 日商中外製藥股份有限公司 | 包含經改變之抗體可變區之抗原結合分子的資料庫 |
| MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| MX388350B (es) * | 2015-05-04 | 2025-03-19 | Cytomx Therapeutics Inc | Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos. |
| KR101997241B1 (ko) | 2015-05-21 | 2019-07-09 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
| US20180185510A1 (en) * | 2015-06-23 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies |
| EP3322800A4 (en) * | 2015-07-13 | 2019-05-01 | University of Utah Research Foundation | PROCESS FOR THE PRODUCTION OF RED BLOOD BODIES AND BLOOD PLATES IN VITRO AND USES THEREOF |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TW202346349A (zh) | 2015-07-31 | 2023-12-01 | 德商安美基研究（慕尼黑）公司 | Dll3及cd3抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| EA201890530A1 (ru) * | 2015-08-20 | 2018-09-28 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения |
| JP2018532990A (ja) | 2015-09-04 | 2018-11-08 | オービーアイ ファーマ，インコーポレイテッド | グリカンアレイおよび使用の方法 |
| US10195209B2 (en) | 2015-11-30 | 2019-02-05 | Abbvie Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
| EP3383909B1 (en) | 2015-11-30 | 2020-06-17 | AbbVie Inc. | Anti-human lrrc15 antibody drug conjugates and methods for their use |
| WO2017134158A1 (en) | 2016-02-03 | 2017-08-10 | Amgen Research (Munich) Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs |
| EA039325B1 (ru) * | 2016-02-03 | 2022-01-13 | Эмджен Рисерч (Мюник) Гмбх | Конструкции биспецифических антител, связывающиеся с дпб3 (dll3) и кд3 (cd3) |
| CN108779242B (zh) | 2016-03-17 | 2021-06-11 | 默克专利股份公司 | 纯化泊洛沙姆的方法 |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| KR20180121786A (ko) * | 2016-03-29 | 2018-11-08 | 오비아이 파머 인코퍼레이티드 | 항체, 제약 조성물 및 방법 |
| EA201892225A1 (ru) | 2016-04-04 | 2019-09-30 | БИОВЕРАТИВ ЮЭсЭй ИНК. | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ |
| KR20250048399A (ko) | 2016-04-22 | 2025-04-08 | 오비아이 파머 인코퍼레이티드 | 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법 |
| JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス，インク． | 単一ドメイン血清アルブミン結合タンパク質 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| TWI767915B (zh) | 2016-06-27 | 2022-06-21 | 加州大學董事會 | Ror-1與btk拮抗劑的組合 |
| US11642400B2 (en) | 2016-07-27 | 2023-05-09 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
| JP7121724B2 (ja) | 2016-07-29 | 2022-08-18 | オービーアイ ファーマ，インコーポレイテッド | ヒト抗体、医薬組成物及び方法 |
| AU2017307616A1 (en) | 2016-08-05 | 2019-02-28 | Allakos, Inc. | Anti-Siglec-7 antibodies for the treatment of cancer |
| US10042362B2 (en) | 2016-11-18 | 2018-08-07 | Waymo Llc | Dynamic routing for autonomous vehicles |
| CA3044274A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
| AU2017364473B2 (en) * | 2016-11-22 | 2024-06-06 | Dendrocyte Biotech Pty Ltd | Anti-CD300f antibody and uses thereof |
| BR112019010602A2 (pt) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | proteínas trispecíficas para psma e métodos de uso |
| US10849973B2 (en) | 2016-11-23 | 2020-12-01 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
| WO2018102795A2 (en) | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| GB201700553D0 (en) * | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| WO2018209304A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| KR102794369B1 (ko) | 2017-08-01 | 2025-04-15 | 에이비 테라퓨틱스 인코퍼레이티드 | 이중특이 항체 및 그의 용도 |
| JP7369121B2 (ja) | 2017-10-11 | 2023-10-25 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | 補体活性を誘発する方法 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| WO2019075359A1 (en) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | TRISPECIFIC PROTEINS AND METHODS OF USE |
| EP3720963A4 (en) | 2017-12-05 | 2021-12-08 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN BINDING MOLECULE INCLUDING A VARIABLE REGION OF MODIFIED ANTIBODIES BINDING TO CD3 AND CD137 |
| JP7314146B2 (ja) | 2017-12-28 | 2023-07-25 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| US11912766B2 (en) | 2018-01-11 | 2024-02-27 | Allakos, Inc. | Anti-Siglec-7 antibodies having reduced effector function |
| EP3773630A1 (en) | 2018-04-03 | 2021-02-17 | Promab Biotechnologies, Inc. | Bcma-car-t cells |
| US20220025037A1 (en) * | 2018-04-03 | 2022-01-27 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting dll3, and use thereof |
| CA3095920A1 (en) * | 2018-04-10 | 2019-10-17 | Amgen Inc. | Chimeric receptors to dll3 and methods of use thereof |
| JP7455388B2 (ja) * | 2018-05-08 | 2024-03-26 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｄｌｌ３抗体及びその使用 |
| US12415860B2 (en) | 2018-05-14 | 2025-09-16 | Harpoon Therapeutics, Inc. | Binding moiety for conditional activation of immunoglobulin molecules |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
| DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CN112955153A (zh) | 2018-08-02 | 2021-06-11 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗肌养蛋白病的用途 |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| CN112912499A (zh) | 2018-08-02 | 2021-06-04 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途 |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12435137B2 (en) | 2018-08-03 | 2025-10-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing two antigen-binding domains that are linked to each other |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| BR112021005769A2 (pt) * | 2018-09-25 | 2021-07-06 | Harpoon Therapeutics Inc | proteínas de ligação a dll3 e métodos de uso |
| WO2020069349A1 (en) * | 2018-09-27 | 2020-04-02 | Colorado State University Research Foundation | Scfv's for live cell imaging and other uses |
| EP4578507A3 (en) | 2018-11-01 | 2025-11-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| SG11202107007VA (en) * | 2018-12-27 | 2021-07-29 | Akeso Biopharma Inc | Antibody against human il-4ra and use thereof |
| WO2020159918A2 (en) | 2019-01-28 | 2020-08-06 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| SG11202108955QA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Antibody molecules that bind to nkp30 and uses thereof |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| SG11202108011UA (en) | 2019-03-01 | 2021-08-30 | Allogene Therapeutics Inc | Dll3 targeting chimeric antigen receptors and binding agents |
| EP3908679A1 (en) * | 2019-03-08 | 2021-11-17 | OncoLab Diagnostics GmbH | Cancer diagnosis and prognosis |
| BR112021016272A2 (pt) * | 2019-04-08 | 2021-11-09 | Phanes Therapeutics Inc | Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos |
| JP7650819B2 (ja) * | 2019-04-24 | 2025-03-25 | ブイオーアール バイオファーマ インコーポレーテッド | 抗－ｃｄ４５抗体薬物コンジュゲート及びその使用 |
| CA3142884A1 (en) * | 2019-06-07 | 2020-12-10 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| AU2020310894A1 (en) * | 2019-07-11 | 2022-02-03 | Memorial Sloan Kettering Cancer Center | DLL3-targeting antibodies and uses thereof |
| WO2021041300A2 (en) * | 2019-08-23 | 2021-03-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| CN112442126B (zh) * | 2019-09-04 | 2022-07-29 | 杭州济元基因科技有限公司 | 一种抗人cs1抗原的单克隆抗体及其car-t细胞 |
| EP3819312A1 (en) * | 2019-11-10 | 2021-05-12 | Amgen, Inc | Dosing regimen for anti-dll3 agents |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| US11692026B2 (en) | 2020-01-10 | 2023-07-04 | Rhode Island Hospital | Antibodies to PfGARP kill Plasmodium falciparum malaria parasites and protect against infection and severe disease |
| US20230226212A1 (en) * | 2020-01-10 | 2023-07-20 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| AU2021206234A1 (en) * | 2020-01-10 | 2022-09-01 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| AU2021205346A1 (en) * | 2020-01-10 | 2022-09-01 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| MX2022008538A (es) * | 2020-01-10 | 2022-08-08 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de la distrofia muscular facioescapulohumeral. |
| EP4093773A4 (en) * | 2020-01-24 | 2024-02-28 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USE FOR THE TREATMENT OF MUSCLE ATROPHY |
| WO2021167952A2 (en) * | 2020-02-20 | 2021-08-26 | The Feinstein Institutes For Medical Research | Agonist antibodies against endoglin and uses thereof |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| BR112022016550A2 (pt) | 2020-02-21 | 2022-11-16 | Harpoon Therapeutics Inc | Proteínas de ligação a flt3 e métodos de uso |
| CN116096751A (zh) * | 2020-02-25 | 2023-05-09 | 璟尚生物制药公司 | 三特异性t细胞接合器 |
| CR20250287A (es) | 2020-03-31 | 2025-08-28 | Chugai Pharmaceutical Co Ltd | Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta (dll3) y sus usos (divisional exp. 2022-0541) |
| JP7736688B2 (ja) | 2020-03-31 | 2025-09-09 | 中外製薬株式会社 | 多重特異性抗原結合分子を製造するための方法 |
| US11242382B2 (en) | 2020-04-20 | 2022-02-08 | Genzyme Corporation | Humanized anti-complement factor Bb antibodies |
| CN115702003A (zh) * | 2020-04-23 | 2023-02-14 | 瑞美德生物医药科技有限公司 | 趋化因子受体4(cxcr4)拮抗剂抗体 |
| MX2022015157A (es) * | 2020-06-02 | 2023-01-16 | Arcus Biosciences Inc | Anticuerpos para tigit. |
| CN116209678A (zh) | 2020-07-01 | 2023-06-02 | 安尔士制药公司 | 抗asgr1抗体缀合物及其用途 |
| AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
| WO2022087316A1 (en) * | 2020-10-21 | 2022-04-28 | La Jolla Institute For Immunology | Chimeric anti-sars-cov2 nucleoprotein antibodies |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| KR20230146522A (ko) | 2021-01-13 | 2023-10-19 | 메모리얼 슬로안 케터링 캔서 센터 | 항-dll3 항체-약물 접합체 |
| KR20230146521A (ko) | 2021-01-13 | 2023-10-19 | 메모리얼 슬로안 케터링 캔서 센터 | 항체-피롤로벤조디아제핀 유도체 접합체 |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| IL309936A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of dystrophinopathy |
| CN113528583A (zh) * | 2021-07-15 | 2021-10-22 | 澳门大学 | 自动化显微注射方法、装置、系统、设备及存储介质 |
| JP2024529504A (ja) | 2021-07-30 | 2024-08-06 | シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド | 抗ｄｌｌ３抗体とその製造方法、その薬物複合体及び使用 |
| CA3229705A1 (en) * | 2021-08-19 | 2023-02-23 | Adicet Therapeutics, Inc. | Methods for detection of membrane bound glypican-3 |
| WO2023053272A1 (en) | 2021-09-29 | 2023-04-06 | Chugai Seiyaku Kabushiki Kaisha | Uses of dll3-targeting multispecific antigen-binding molecules |
| CN119183457A (zh) | 2022-04-15 | 2024-12-24 | 达因疗法公司 | 用于治疗强直性肌营养不良的肌肉靶向复合物和制剂 |
| US20250270328A1 (en) * | 2022-05-18 | 2025-08-28 | The Brigham And Women's Hospital, Inc. | Klrb1 binding agents and methods of use thereof |
| CN119019548B (zh) * | 2022-07-05 | 2025-06-24 | 东莞市朋志生物科技有限公司 | 抗甲型流感病毒抗体、检测甲型流感病毒的试剂和试剂盒 |
| CN116355079B (zh) * | 2022-08-19 | 2023-12-26 | 上海迈科康生物科技有限公司 | 检测重组人轮状病毒vp8抗原（vp8 p[8]）的单克隆抗体及其应用 |
| CA3265385A1 (en) | 2022-08-22 | 2024-02-29 | Abdera Therapeutics Inc | DLL3 BINDING MOLECULES AND THEIR USES |
| CN116731184B (zh) * | 2022-11-25 | 2024-06-14 | 厦门康基生物科技有限公司 | 一种特异性结合Taq酶的单克隆抗体F6H12及其应用 |
| AR131163A1 (es) | 2022-11-25 | 2025-02-19 | Chugai Pharmaceutical Co Ltd | Métodos para producir proteínas |
| CN120303300A (zh) * | 2022-12-08 | 2025-07-11 | 安进公司 | 治疗表达dll3的癌症的方法 |
| CN116173202A (zh) * | 2022-12-28 | 2023-05-30 | 北京东方百泰生物科技股份有限公司 | 一种抗lilrb4单克隆抗体注射制剂 |
| US20250034210A1 (en) * | 2023-06-14 | 2025-01-30 | Mariana Oncology Inc. | Dll3 targeting peptides and constructs thereof |
| WO2024259147A1 (en) * | 2023-06-14 | 2024-12-19 | Mariana Oncology Inc. | Dll3 targeting peptides and constructs thereof |
| AU2024303797A1 (en) * | 2023-06-14 | 2025-12-04 | Mariana Oncology Inc. | Dll3 targeting peptides and constructs thereof |
| CN119490592B (zh) * | 2023-08-14 | 2025-11-18 | 东莞市朋志生物科技有限公司 | 一种抗κ型轻链抗体及其应用 |
| CN116966202B (zh) * | 2023-09-22 | 2023-12-01 | 再少年(北京)生物科技有限公司 | iPS诱导定向分化成的神经干细胞联合药物用于治疗阿尔茨海默症的用途 |
| WO2025085796A1 (en) * | 2023-10-18 | 2025-04-24 | Memorial Sloan-Kettering Cancer Center | Armored immunoresponsive cells targeting dll3 and uses thereof |
| WO2025179168A1 (en) * | 2024-02-22 | 2025-08-28 | Mariana Oncology Inc. | Synthesis of dll3-binding peptides |
| CN120137041B (zh) * | 2025-03-14 | 2025-11-28 | 深圳市欧安蒂生物科技有限公司 | 一种抗gprc5d抗体及其在car-t中的应用 |
| CN120350014B (zh) * | 2025-06-26 | 2025-08-22 | 上海交通大学医学院附属仁济医院 | 核酸适体、核酸适体衍生物及其应用 |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901464A (fr) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Procédé d'obtention de vanilline |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| FI102355B (fi) | 1988-02-11 | 1998-11-30 | Squibb Bristol Myers Co | Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5879936A (en) | 1988-04-18 | 1999-03-09 | Aluguisse Holding A.G. | Recombinant DNA methods, vectors and host cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| DE69132709T2 (de) | 1990-06-29 | 2002-06-20 | Large Scale Biology Corp., Vacaville | Melaninproduktion durch transformierte mikroorganismen |
| JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| KR100246529B1 (ko) | 1990-12-14 | 2000-04-01 | 스티븐 에이. 서윈. 엠.디. | 수용체 관련된 신호 변환 경로를 위한 키메라 사슬 |
| JP4146512B2 (ja) | 1991-03-01 | 2008-09-10 | ダイアックス コープ． | 小型タンパク質 |
| ES2223040T3 (es) | 1991-04-10 | 2005-02-16 | The Scripps Research Institute | Bibliotecas de receptor heterodimerilo que usan fagemidos. |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
| CA2141602A1 (en) | 1992-08-26 | 1994-03-03 | Philip Leder | Use of the cytokine ip-10 as an anti-tumor agent |
| RU2139731C1 (ru) | 1992-11-13 | 1999-10-20 | Айдек Фармасьютикалс Корпорейшн (US | Способ лечения, антитела, гибридома |
| US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| DE69424687T2 (de) | 1993-03-09 | 2000-09-07 | Genzyme Corp., Cambridge | Verfahren zur isolierung von proteinen aus milch |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| WO1996002701A1 (en) | 1994-07-13 | 1996-02-01 | Sca Hygiene Paper Ab | Method of producing a nonwoven material and nonwoven material produced according to the method |
| NZ292124A (en) | 1994-07-29 | 1998-10-28 | Smithkline Beecham Plc | Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment |
| US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| DK0871490T3 (da) | 1995-12-22 | 2003-07-07 | Bristol Myers Squibb Co | Forgrenede hydrazonlinkere |
| WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| KR20030096450A (ko) | 1996-03-22 | 2003-12-31 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 고사 유도 분자 ⅱ |
| US20030180784A1 (en) * | 1997-04-04 | 2003-09-25 | Millennium Pharmaceuticals, Inc. | Novel human Delta3 compositions and therapeutic and diagnostic uses therefor |
| AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| ES2303358T3 (es) | 1997-11-03 | 2008-08-01 | Human Genome Sciences, Inc. | Vegi, un inhibidor de la angiogenesis y el crecimiento tumoral. |
| CA2312208C (en) | 1997-12-05 | 2011-01-25 | The Scripps Research Institute | Humanization of murine antibody |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| ATE320436T1 (de) | 1998-08-27 | 2006-04-15 | Spirogen Ltd | Dimere pyrrolobenzodiazepine |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6908748B2 (en) | 1999-07-29 | 2005-06-21 | Kenji Sobue | Genes associated with the maintenance of differentiation of smooth muscle cells |
| US6703221B1 (en) | 1999-08-19 | 2004-03-09 | Chiron Corporation | Notch receptor ligands and uses thereof |
| WO2001012664A2 (en) | 1999-08-19 | 2001-02-22 | Chiron Corporation | Notch receptor ligands and uses thereof |
| EP1278767A4 (en) | 2000-04-12 | 2003-11-12 | Principia Pharmaceutical Corp | ALBUMIN FUSED PROTEINS |
| WO2002014358A2 (en) | 2000-08-11 | 2002-02-21 | Eli Lilly And Company | Novel secreted proteins and their uses |
| US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
| DE10131904A1 (de) | 2001-07-04 | 2003-01-16 | Putzmeister Ag | Vorrichtung zum Fördern von fließ- oder schüttfähigem Fördergut |
| AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| US20040001835A1 (en) | 2002-03-04 | 2004-01-01 | Medimmune, Inc. | Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
| CA2832136C (en) | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| JP4884224B2 (ja) | 2003-05-09 | 2012-02-29 | ディアデクサス インコーポレーテッド | Ｏｖｒ１１０抗体組成物および使用方法 |
| WO2005014854A1 (en) | 2003-08-08 | 2005-02-17 | Licentia, Ltd. | Materials and methods for colorectal cancer screening, diagnosis, and therapy |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| ES2456325T3 (es) | 2003-11-06 | 2014-04-22 | Seattle Genetics, Inc. | Compuestos de monometilvalina capaces de conjugación con ligandos |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| PT2270010E (pt) | 2004-03-01 | 2012-03-12 | Spirogen Ltd | Derivados de 11-hidroxi-5h-pirrolo[2,1-c][1,4]benzodiazepin- 5-ona como intermediários chave para a preparação de pirrolobenzodiazepinas substituídas em c2 |
| US7189710B2 (en) | 2004-03-30 | 2007-03-13 | Council Of Scientific And Industrial Research | C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers |
| FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
| JP4840939B2 (ja) | 2004-08-04 | 2011-12-21 | アムジェン インコーポレイテッド | Ｄｋｋ−１に対する抗体 |
| BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| WO2007111733A2 (en) | 2005-12-16 | 2007-10-04 | Genentech, Inc. | Method for diagnosing, prognosing and treating glioma |
| EP2216339A1 (en) | 2006-01-16 | 2010-08-11 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis |
| SI1813614T1 (sl) | 2006-01-25 | 2012-01-31 | Sanofi 174 | Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate |
| US8133857B2 (en) | 2006-03-07 | 2012-03-13 | The Brigham and Women's FHospital, Inc. | NOTCH inhibition in the treatment of atherosclerosis |
| JP2009539374A (ja) | 2006-06-06 | 2009-11-19 | ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション | 腫瘍性幹細胞が富化された組成物及びそれを含む方法 |
| LT3207941T (lt) | 2006-09-07 | 2020-04-10 | Scott & White Memorial Hospital | Būdai ir kompozicijos difterijos toksino ir interleukino 3 konjugatų pagrindu |
| US7825267B2 (en) | 2006-09-08 | 2010-11-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Synthesis of FR901464 and analogs with antitumor activity |
| JP5378795B2 (ja) | 2006-10-20 | 2013-12-25 | 中外製薬株式会社 | 抗ｈｂ−ｅｇｆ抗体を有効成分として含む医薬組成物 |
| US8309354B2 (en) | 2007-01-22 | 2012-11-13 | Macrogenics West, Inc. | Human cancer stem cells |
| EP2764874A1 (en) | 2007-07-17 | 2014-08-13 | The General Hospital Corporation | Methods to identify and enrich for populations of ovarian cancer stem cells and somatic stem cells and uses thereof |
| EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| CA2697922A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
| WO2009043051A2 (en) | 2007-09-27 | 2009-04-02 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
| JP2011516520A (ja) * | 2008-04-07 | 2011-05-26 | アブリンクス エン．ヴェー． | Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用 |
| US8384551B2 (en) | 2008-05-28 | 2013-02-26 | MedHab, LLC | Sensor device and method for monitoring physical stresses placed on a user |
| WO2010037134A2 (en) | 2008-09-29 | 2010-04-01 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
| WO2010081171A2 (en) | 2009-01-12 | 2010-07-15 | Cyntellect, Inc. | Laser mediated sectioning and transfer of cell colonies |
| US20110020221A1 (en) | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
| SI2530091T1 (en) * | 2010-01-29 | 2018-06-29 | Chugai Seiyaku Kabushiki Kaisha | PROTITELO ANTI-DLL3 |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| CN103068405A (zh) | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
| CN102933236B (zh) * | 2010-04-15 | 2014-10-08 | 斯皮罗根有限公司 | 吡咯并苯二氮卓类及其结合物 |
| ES2623057T3 (es) | 2010-04-15 | 2017-07-10 | Medimmune Limited | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas |
| CA2809864A1 (en) | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US20130061342A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| PL3409287T3 (pl) | 2010-09-29 | 2021-09-27 | Agensys, Inc. | Koniugaty leków i przeciwciał (adc), które wiążą białka 191p4d12 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| MX347590B (es) | 2011-03-02 | 2017-05-03 | Roche Glycart Ag | Anticuerpos del cea. |
| CN103987718A (zh) | 2011-09-20 | 2014-08-13 | 斯皮罗根有限公司 | 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓 |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| KR20200110476A (ko) | 2011-11-16 | 2020-09-23 | 베링거 인겔하임 인터내셔날 게엠베하 | 항 ｉｌ-36ｒ 항체 |
| PL2817338T3 (pl) | 2012-02-24 | 2017-12-29 | Abbvie Stemcentrx Llc | Modulatory DLL3 i sposoby zastosowania |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| PL2958944T3 (pl) | 2013-02-22 | 2019-09-30 | Abbvie Stemcentrx Llc | Koniugaty przeciwciało anty-DLL3-PBD i ich zastosowania |
| US9683039B2 (en) | 2013-03-14 | 2017-06-20 | New York University | Notch agonists for the treatment of cancer |
| MX2016002545A (es) | 2013-08-28 | 2016-06-17 | Stemcentrx Inc | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y metodos de uso. |
| KR20160044042A (ko) | 2013-08-28 | 2016-04-22 | 스템센트알엑스 인코포레이티드 | 부위-특이적 항체 접합 방법 및 조성물 |
| CA2939941A1 (en) | 2014-02-21 | 2015-08-27 | Abbvie Stemcentrx Llc | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| EP3209334A2 (en) | 2014-10-20 | 2017-08-30 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
| WO2018026742A1 (en) | 2016-08-01 | 2018-02-08 | Askgene Pharma Inc. | Novel antibody-albumin-drug conjugates (aadc) and methods for using them |
-
2013
- 2013-02-22 PL PL13707525T patent/PL2817338T3/pl unknown
- 2013-02-22 PE PE2019000670A patent/PE20190658A1/es unknown
- 2013-02-22 PT PT137075255T patent/PT2817338T/pt unknown
- 2013-02-22 WO PCT/US2013/027391 patent/WO2013126746A2/en not_active Ceased
- 2013-02-22 CN CN201380010475.2A patent/CN104520324A/zh active Pending
- 2013-02-22 ME MEP-2017-185A patent/ME02928B/me unknown
- 2013-02-22 SM SM20170467T patent/SMT201700467T1/it unknown
- 2013-02-22 DK DK13707525.5T patent/DK2817338T3/en active
- 2013-02-22 HU HUE13707525A patent/HUE037021T2/hu unknown
- 2013-02-22 SG SG11201405131XA patent/SG11201405131XA/en unknown
- 2013-02-22 CA CA2865404A patent/CA2865404C/en active Active
- 2013-02-22 RU RU2014138474A patent/RU2014138474A/ru not_active Application Discontinuation
- 2013-02-22 NZ NZ628804A patent/NZ628804A/en not_active IP Right Cessation
- 2013-02-22 EP EP16164549.4A patent/EP3093293A1/en not_active Withdrawn
- 2013-02-22 ES ES13707525.5T patent/ES2645272T3/es active Active
- 2013-02-22 CA CA3050672A patent/CA3050672A1/en not_active Abandoned
- 2013-02-22 ES ES16164567T patent/ES2812849T3/es active Active
- 2013-02-22 EP EP13707525.5A patent/EP2817338B1/en active Active
- 2013-02-22 EP EP16164567.6A patent/EP3095797B1/en active Active
- 2013-02-22 AU AU2013203459A patent/AU2013203459B2/en not_active Ceased
- 2013-02-22 MX MX2014010074A patent/MX2014010074A/es unknown
- 2013-02-22 BR BR112014020826A patent/BR112014020826A8/pt not_active Application Discontinuation
- 2013-02-22 KR KR1020147026844A patent/KR20150003169A/ko not_active Ceased
- 2013-02-22 EP EP16164551.0A patent/EP3093294A1/en not_active Withdrawn
- 2013-02-22 SI SI201330800T patent/SI2817338T1/sl unknown
- 2013-02-22 RS RS20171006A patent/RS56443B1/sr unknown
- 2013-02-22 PE PE2014001295A patent/PE20150090A1/es active IP Right Grant
- 2013-02-22 SG SG10201806867VA patent/SG10201806867VA/en unknown
- 2013-02-22 LT LTEP13707525.5T patent/LT2817338T/lt unknown
- 2013-02-22 HR HRP20171549TT patent/HRP20171549T1/hr unknown
- 2013-02-22 JP JP2014558882A patent/JP6089047B2/ja not_active Expired - Fee Related
-
2014
- 2014-08-17 IL IL234155A patent/IL234155B/en active IP Right Grant
- 2014-08-20 PH PH12014501876A patent/PH12014501876A1/en unknown
- 2014-08-21 MX MX2018010548A patent/MX2018010548A/es unknown
- 2014-08-22 US US14/466,945 patent/US9089616B2/en not_active Expired - Fee Related
- 2014-08-22 US US14/466,951 patent/US9089617B2/en not_active Expired - Fee Related
- 2014-08-22 US US14/466,842 patent/US9089615B2/en not_active Expired - Fee Related
- 2014-08-22 CL CL2014002240A patent/CL2014002240A1/es unknown
- 2014-08-22 US US14/466,948 patent/US9090683B2/en not_active Expired - Fee Related
- 2014-08-22 CO CO14184798A patent/CO7111274A2/es unknown
- 2014-08-22 US US14/466,939 patent/US8986972B2/en active Active
- 2014-08-22 US US14/466,941 patent/US9107961B2/en not_active Expired - Fee Related
-
2015
- 2015-01-19 HK HK17104910.0A patent/HK1231486A1/en unknown
- 2015-01-19 HK HK17104918.2A patent/HK1231488A1/en unknown
- 2015-01-19 HK HK17104908.4A patent/HK1231485A1/en unknown
- 2015-06-08 US US14/733,874 patent/US9155803B1/en not_active Expired - Fee Related
- 2015-06-17 US US14/742,576 patent/US9133271B1/en not_active Expired - Fee Related
- 2015-07-23 US US14/807,789 patent/US9173959B1/en active Active
- 2015-09-18 US US14/859,242 patent/US9353182B2/en not_active Expired - Fee Related
-
2016
- 2016-01-11 US US14/992,714 patent/US9334318B1/en active Active
- 2016-01-25 US US15/005,918 patent/US9345784B1/en not_active Expired - Fee Related
- 2016-01-25 US US15/005,993 patent/US9358304B1/en not_active Expired - Fee Related
- 2016-01-25 US US15/005,962 patent/US9352051B1/en not_active Expired - Fee Related
- 2016-02-19 JP JP2016030269A patent/JP6010241B2/ja not_active Expired - Fee Related
- 2016-02-19 JP JP2016030270A patent/JP2016098233A/ja active Pending
- 2016-04-21 US US15/135,517 patent/US9486537B2/en not_active Expired - Fee Related
- 2016-04-21 US US15/135,546 patent/US9481727B2/en not_active Expired - Fee Related
- 2016-04-21 US US15/135,542 patent/US9480757B2/en not_active Expired - Fee Related
- 2016-06-22 CL CL2016001616A patent/CL2016001616A1/es unknown
- 2016-09-15 US US15/266,894 patent/US10137204B2/en active Active
- 2016-10-14 AU AU2016244333A patent/AU2016244333B2/en not_active Ceased
-
2017
- 2017-05-30 US US15/608,991 patent/US9878053B2/en active Active
- 2017-05-30 US US15/608,996 patent/US9775916B1/en not_active Expired - Fee Related
- 2017-05-30 US US15/608,995 patent/US9764042B1/en not_active Expired - Fee Related
- 2017-05-30 US US15/608,988 patent/US9770518B1/en not_active Expired - Fee Related
- 2017-06-07 US US15/616,192 patent/US9861708B2/en active Active
- 2017-06-07 US US15/616,800 patent/US9855343B2/en active Active
- 2017-09-01 US US15/694,629 patent/US9937268B2/en not_active Expired - Fee Related
- 2017-09-01 US US15/694,627 patent/US9931421B2/en not_active Expired - Fee Related
- 2017-09-01 US US15/694,622 patent/US9867887B1/en active Active
- 2017-09-01 US US15/694,602 patent/US9931420B2/en not_active Expired - Fee Related
- 2017-10-20 CY CY20171101098T patent/CY1119590T1/el unknown
-
2018
- 2018-05-29 JP JP2018102094A patent/JP2018162257A/ja active Pending
- 2018-10-03 IL IL262110A patent/IL262110A/en unknown
- 2018-10-25 US US16/170,848 patent/US20190046656A1/en not_active Abandoned
- 2018-12-19 AU AU2018282328A patent/AU2018282328A1/en not_active Abandoned
-
2019
- 2019-04-12 US US16/382,868 patent/US20190247510A1/en not_active Abandoned
- 2019-12-06 US US16/706,174 patent/US11033634B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016098233A5 (enExample) | ||
| JP2025143392A (ja) | 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート | |
| JP2015509947A5 (enExample) | ||
| ME02928B (me) | Dll3 modulatori i metode upotrebe | |
| JP2012522513A5 (enExample) | ||
| RU2015106673A (ru) | Антитела к рецептору эндотелина типа в (etbr) и иммуноконъюгаты | |
| JP2016538318A5 (enExample) | ||
| JP2018127469A5 (enExample) | ||
| CA2926325C (en) | Anti-folr1 immunoconjugate dosing regimens | |
| RU2019138337A (ru) | Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии | |
| JP2012522512A5 (enExample) | ||
| JP2016528882A5 (enExample) | ||
| RU2011144119A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2015523380A5 (enExample) | ||
| JP2014139173A5 (enExample) | ||
| JP2015528818A5 (enExample) | ||
| AU2016293606A1 (en) | Cysteine-substituted immunoglobulins | |
| JP2010518115A5 (enExample) | ||
| HRP20191169T1 (hr) | Konjugati antidll3-protutijelo-pbd i njihove uporabe | |
| JP2016531915A5 (enExample) | ||
| IL278574B1 (en) | Compounds acting on glycans and methods of using them | |
| RU2016133846A (ru) | Конъюгат лиганд - цитотоксическое лекарственное средство, способ его получения и его применения | |
| JP2015533781A5 (enExample) | ||
| WO2015149018A1 (en) | Anti-folr1 immunoconjugate dosing regimens | |
| RU2016109247A (ru) | Способы применения антител к lgr5 |